Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cells trained to kill HPV tumors show promise in early trial

NCT ID NCT02379520

First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 23 times

Summary

This study tested a new treatment for people with HPV-related cancers that returned or didn't respond to standard care. Researchers took blood from 32 patients, grew special immune cells (HPVST cells) that target HPV-infected cancer cells, and gave them back to patients. The goal was to find a safe dose, see how long the cells last, and check for side effects. Some patients also received the drug Nivolumab to boost the immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.